BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38099606)

  • 1. Raman classification of selected subtypes of acute lymphoblastic leukemia (ALL).
    Adamczyk A; Nowakowska AM; Jakubowska J; Zabczynska M; Bartoszek M; Kashyrskaya S; Fatla A; Stawoski K; Siakala K; Pastorczak A; Ostrowska K; Mlynarski W; Majzner K; Baranska M
    Analyst; 2024 Jan; 149(2):571-581. PubMed ID: 38099606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging molecular subtypes and therapies in acute lymphoblastic leukemia.
    Davis K; Sheikh T; Aggarwal N
    Semin Diagn Pathol; 2023 May; 40(3):202-215. PubMed ID: 37120350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Raman spectroscopy can recognize the KMT2A rearrangement as a distinct subtype of leukemia.
    Leszczenko P; Nowakowska AM; Jakubowska J; Pastorczak A; Zabczynska M; Mlynarski W; Baranska M; Ostrowska K; Majzner K
    Spectrochim Acta A Mol Biomol Spectrosc; 2024 Jun; 314():124173. PubMed ID: 38520957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards Raman-Based Screening of Acute Lymphoblastic Leukemia-Type B (B-ALL) Subtypes.
    Leszczenko P; Borek-Dorosz A; Nowakowska AM; Adamczyk A; Kashyrskaya S; Jakubowska J; Ząbczyńska M; Pastorczak A; Ostrowska K; Baranska M; Marzec KM; Majzner K
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucin 4 protein is expressed in B-acute lymphoblastic leukemia and is restricted to BCR::ABL1-positive and BCR::ABL-like subtypes.
    Gestrich CK; De Lancy SJ; Kresak A; Sinno MG; Yalley A; Pateva I; Meyerson H; Shetty S; Oduro KA
    Hum Pathol; 2023 Jun; 136():75-83. PubMed ID: 37023866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCR-ABL1-like acute lymphoblastic leukaemia: From bench to bedside.
    Boer JM; den Boer ML
    Eur J Cancer; 2017 Sep; 82():203-218. PubMed ID: 28709134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCR/ABL1-Like Acute Lymphoblastic Leukemia: From Diagnostic Approaches to Molecularly Targeted Therapy.
    Płotka A; Lewandowski K
    Acta Haematol; 2022; 145(2):122-131. PubMed ID: 34818644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High incidence of RAS pathway mutations among sentinel genetic lesions of Korean pediatric BCR-ABL1-like acute lymphoblastic leukemia.
    Lee JW; Kim Y; Cho B; Kim S; Jang PS; Lee J; Cho H; Lee GD; Chung NG; Kim M
    Cancer Med; 2020 Jul; 9(13):4632-4639. PubMed ID: 32378810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Commonly Assessed Markers in Childhood BCP-ALL Diagnostic Panels and Their Association with Genetic Aberrations and Outcome Prediction.
    Kulis J; Sędek Ł; Słota Ł; Perkowski B; Szczepański T
    Genes (Basel); 2022 Jul; 13(8):. PubMed ID: 36011285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases.
    Li JF; Dai YT; Lilljebjörn H; Shen SH; Cui BW; Bai L; Liu YF; Qian MX; Kubota Y; Kiyoi H; Matsumura I; Miyazaki Y; Olsson L; Tan AM; Ariffin H; Chen J; Takita J; Yasuda T; Mano H; Johansson B; Yang JJ; Yeoh AE; Hayakawa F; Chen Z; Pui CH; Fioretos T; Chen SJ; Huang JY
    Proc Natl Acad Sci U S A; 2018 Dec; 115(50):E11711-E11720. PubMed ID: 30487223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.
    van der Veer A; Waanders E; Pieters R; Willemse ME; Van Reijmersdal SV; Russell LJ; Harrison CJ; Evans WE; van der Velden VH; Hoogerbrugge PM; Van Leeuwen F; Escherich G; Horstmann MA; Mohammadi Khankahdani L; Rizopoulos D; De Groot-Kruseman HA; Sonneveld E; Kuiper RP; Den Boer ML
    Blood; 2013 Oct; 122(15):2622-9. PubMed ID: 23974192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.
    Boer JM; Steeghs EM; Marchante JR; Boeree A; Beaudoin JJ; Beverloo HB; Kuiper RP; Escherich G; van der Velden VH; van der Schoot CE; de Groot-Kruseman HA; Pieters R; den Boer ML
    Oncotarget; 2017 Jan; 8(3):4618-4628. PubMed ID: 27894077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High STAP1 expression in DUX4-rearranged cases is not suitable as therapeutic target in pediatric B-cell precursor acute lymphoblastic leukemia.
    Steeghs EMP; Bakker M; Hoogkamer AQ; Boer JM; Hartman QJ; Stalpers F; Escherich G; de Haas V; de Groot-Kruseman HA; Pieters R; den Boer ML
    Sci Rep; 2018 Jan; 8(1):693. PubMed ID: 29330417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunophenotypic characteristics of ZNF384 rearrangement compared with BCR-ABL1, KMT2A rearrangement, and other adult B-cell precursor acute lymphoblastic leukemia.
    Wang YZ; Qin YZ; Chang Y; Yuan XY; Chen WM; He LL; Hao L; Shi WH; Jiang Q; Jiang H; Huang XJ; Liu YR
    Cytometry B Clin Cytom; 2022 Sep; 102(5):360-369. PubMed ID: 35735203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High frequency of BTG1 deletions in patients with BCR-ABL1-positive acute leukemia.
    Xie J; Wang Q; Wang Q; Yao H; Wen L; Ma L; Wu D; Chen S
    Cancer Genet; 2014 May; 207(5):226-30. PubMed ID: 24998463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis.
    Herold T; Schneider S; Metzeler KH; Neumann M; Hartmann L; Roberts KG; Konstandin NP; Greif PA; Bräundl K; Ksienzyk B; Huk N; Schneider I; Zellmeier E; Jurinovic V; Mansmann U; Hiddemann W; Mullighan CG; Bohlander SK; Spiekermann K; Hoelzer D; Brüggemann M; Baldus CD; Dreyling M; Gökbuget N
    Haematologica; 2017 Jan; 102(1):130-138. PubMed ID: 27561722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCR-ABL1-like B-Lymphoblastic Leukemia/Lymphoma with FOXP1-ABL1 Rearrangement: Comprehensive Laboratory Identification Allowing Tyrosine Kinase Inhibitor Use.
    Yenamandra AK; Kaviany S; Borinstein SC; Friedman DL; Kovach AE
    Lab Med; 2019 Oct; 50(4):401-405. PubMed ID: 30938769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement.
    Bomken S; Enshaei A; Schwalbe EC; Mikulasova A; Dai Y; Zaka M; Fung KTM; Bashton M; Lim H; Jones L; Karataraki N; Winterman E; Ashby C; Attarbaschi A; Bertrand Y; Bradtke J; Buldini B; Burke GAA; Cazzaniga G; Gohring G; De Groot-Kruseman HA; Haferlach C; Nigro LL; Parihar M; Plesa A; Seaford E; Sonneveld E; Strehl S; Van der Velden VHJ; Rand V; Hunger SP; Harrison CJ; Bacon CM; Van Delft FW; Loh ML; Moppett J; Vormoor J; Walker BA; Moorman AV; Russell LJ
    Haematologica; 2023 Mar; 108(3):717-731. PubMed ID: 35484682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation of RNA sequencing and array CGH in the diagnostic workflow of the AIEOP-BFM ALL 2017 trial on acute lymphoblastic leukemia.
    Schieck M; Lentes J; Thomay K; Hofmann W; Behrens YL; Hagedorn M; Ebersold J; Davenport CF; Fazio G; Möricke A; Buchmann S; Alten J; Cario G; Schrappe M; Bergmann AK; Stanulla M; Steinemann D; Schlegelberger B; Cazzaniga G; Göhring G
    Ann Hematol; 2020 Apr; 99(4):809-818. PubMed ID: 32078009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normal and Aberrant TALE-Class Homeobox Gene Activities in Pro-B-Cells and B-Cell Precursor Acute Lymphoblastic Leukemia.
    Nagel S; Meyer C
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.